Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
102
Completed, industry sponsors, Rare and genetic disease, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed102
102 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseasePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03737214 · 107 participants · Start Dec 18, 2018 · Primary completion Aug 31, 2026
Drug: Lucerastat · For: Fabry Disease
Sites: Birmingham, Alabama; Irvine, California; Oakland, California · 42 sites in all
- A Long-Term Safety Study of PTC923 in Participants With PhenylketonuriaPivotal-lookingCompleted
PTC TherapeuticsIndustry
NCT05166161 · 247 participants · Start Feb 14, 2022 · Primary completion Jul 21, 2026
Drug: PTC923 · For: Phenylketonuria
Sites: Aurora, Colorado; Gainesville, Florida; Indianapolis, Indiana · 46 sites in all
- Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03485677 · 57 participants · Start Apr 11, 2018 · Primary completion Dec 26, 2025
Drug: Eliglustat GZ385660; Imiglucerase GZ437843 · For: Gaucher's Disease Type I; Gaucher's Disease Type III
Sites: Buenos Aires, Argentina; Calgary, Canada; Vancouver, Canada · 21 sites in all
- Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease PatientsPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT03614234 · 29 participants · Start Nov 13, 2018 · Primary completion Apr 13, 2026
Drug: pegunigalsidase alfa · For: Fabry Disease
Sites: Birmingham, Alabama; Atlanta, Georgia; Iowa City, Iowa · 14 sites in all
- Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT03566017 · 97 participants · Start Sep 16, 2018 · Primary completion Jan 21, 2025
Drug: pegunigalsidase alfa · For: Fabry Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 30 sites in all
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaPivotal-lookingCompleted
QED Therapeutics, a BridgeBio companyIndustry
NCT06164951 · 114 participants · Start Nov 10, 2023 · Primary completion Dec 18, 2025
Drug: Infigratinib 0.25 mg/kg/day; Placebo Comparator 0.25 mg/kg/day · For: Achondroplasia
Sites: San Francisco, California; Aurora, Colorado; Baltimore, Maryland · 27 sites in all
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)Pivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT04138277 · 119 participants · Start Dec 18, 2019 · Primary completion Dec 31, 2024
Drug: AT2221; ATB200 · For: Pompe Disease (Late-onset)
Sites: Little Rock, Arkansas; Irvine, California; Gainesville, Florida · 60 sites in all
- Switch Over Study of Biosimilar Agalsidase Beta for Fabry DiseasePivotal-lookingCompleted
Bio Sidus SAIndustry
NCT05843916 · 20 participants · Start Dec 13, 2022 · Primary completion Sep 19, 2024
Drug: Recombinant human alpha galactosidase A (agalsidase beta); Recombinant human alpha-galactosidase A (agalsidase beta) · For: Fabry Disease
Sites: Pergamino, Argentina; San Isidro, Argentina; Buenos Aires, Argentina · 5 sites in all
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT04049760 · 16 participants · Start Oct 11, 2019 · Primary completion Nov 29, 2024
Drug: migalastat HCl 150 mg · For: Fabry Disease
Sites: Tampa, Florida; Atlanta, Georgia; Minneapolis, Minnesota · 6 sites in all
- An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)Pivotal-lookingCompleted
GC Biopharma CorpIndustry
NCT07344376 · 30 participants · Start May 23, 2018 · Primary completion Dec 30, 2022
Drug: Hunterase · For: MPS II; Hunter Syndrome (MPS II); Hunter Syndrome and 2 more
Sites: Seoul, South Korea
- Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep®Pivotal-lookingCompleted
NTC srlIndustry
NCT04759885 · 886 participants · Start Jun 18, 2020 · Primary completion Jul 16, 2021
Drug: Phase II: NTC015 low dose; Phase II: NTC015 medium dose and 3 more · For: Elective Colonoscopy
Sites: Avignon, France; Lyon, France; Montpellier, France · 35 sites in all
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT03729362 · 125 participants · Start Dec 4, 2018 · Primary completion Dec 15, 2020
Drug: Cipaglucosidase Alfa; Miglustat and 2 more · For: Pompe Disease (Late-onset)
Sites: Phoenix, Arizona; Little Rock, Arkansas; Irvine, California · 73 sites in all
- A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseasePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT05529992 · 20 participants · Start Jan 3, 2023 · Primary completion Aug 5, 2024
Drug: Velaglucerase Alfa · For: Gaucher Disease
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 10 sites in all
- Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT02412787 · 56 participants · Start Apr 14, 2015 · Primary completion Apr 18, 2024
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 9 sites in all
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT01242202 · 113 participants · Start Oct 21, 2010 · Primary completion May 25, 2012
Drug: ipragliflozin; alpha glucosidase inhibitor · For: Type 2 Diabetes Mellitus
Sites: Chūbu, Japan; Hokkaido, Japan; Kansai, Japan · 6 sites in all
- Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher DiseasePivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00319046 · 42 participants · Start Feb 1, 2006 · Primary completion Jun 1, 2010
Drug: Miglustat · For: Gaucher Disease Type 1
- Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With CystinosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01744782 · 17 participants · Start Dec 20, 2012 · Primary completion Dec 13, 2016
Drug: RP103 · For: Cystinosis
Sites: Chicago, Illinois; São Paulo, Brazil
- Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in CystinosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01733316 · 41 participants · Start Jan 31, 2013 · Primary completion Feb 2015
Drug: RP103; Cystagon® · For: Cystinosis
Sites: San Francisco, California; Stanford, California; Atlanta, Georgia · 14 sites in all
- Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01197378 · 60 participants · Start Aug 27, 2010 · Primary completion Jun 26, 2017
Drug: Cysteamine Bitartrate Delayed-release Capsules · For: Cystinosis
Sites: San Francisco, California; Stanford, California; Atlanta, Georgia · 10 sites in all
- Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With CystinosisPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01000961 · 43 participants · Start Jun 2010 · Primary completion Jun 2011
Drug: Cystagon® (Cysteamine Bitartrate); Cysteamine Bitartrate Delayed-release Capsules (RP103) · For: Cystinosis
Sites: Stanford, California; Atlanta, Georgia; Chicago, Illinois · 8 sites in all
- Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type CPivotal-lookingCompleted
ZevraDenmarkIndustry
NCT02612129 · 50 participants · Start Jun 14, 2016 · Primary completion Jun 25, 2018
Drug: arimoclomol; Placebo · For: Niemann-Pick Disease, Type C
Sites: Oakland, California; Rochester, Minnesota; Copenhagen, Denmark · 14 sites in all
- Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02004691 · 36 participants · Start Dec 18, 2015 · Primary completion Mar 15, 2021
Drug: placebo (saline); Olipudase alfa · For: Sphingomyelin Lipidosis
Sites: San Francisco, California; Decatur, Georgia; The Bronx, New York · 24 sites in all
- A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseasePivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04974749 · 20 participants · Start May 1, 2022 · Primary completion Jan 3, 2024
Drug: REPLAGAL · For: Fabry Disease
Sites: Beijing, China; Changsha, China; Chengdu, China · 6 sites in all
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseasePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03425539 · 118 participants · Start Jun 21, 2018 · Primary completion Aug 17, 2021
Drug: Lucerastat; Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Irvine, California; Oakland, California · 49 sites in all
- Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I PatientsPivotal-lookingCompleted
CinnagenIndustry
NCT06406153 · 12 participants · Start Sep 10, 2022 · Primary completion Aug 12, 2023
Drug: Laronidase; Antihistamine and 1 more · For: Mucopolysaccharidosis Type 1
Sites: Mashhad, Iran; Tehran, Iran · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.